Rohto Pharmaceutical Co Ltd
TSE:4527
Rohto Pharmaceutical Co Ltd
TSE:4527
Price:
2 866
JPY
2.93%
Market Closed
Market Cap:
676.9B
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Rohto Pharmaceutical Co Ltd
2866
+81.5 (+2.93%)
| 52 Week Range |
2 676.5
3 669
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Rohto Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical Co Ltd
| Current Assets | 204.9B |
| Cash & Short-Term Investments | 64.5B |
| Receivables | 68.5B |
| Other Current Assets | 71.9B |
| Non-Current Assets | 203.4B |
| Long-Term Investments | 48B |
| PP&E | 88.5B |
| Intangibles | 58B |
| Other Non-Current Assets | 8.9B |
| Current Liabilities | 111.1B |
| Accounts Payable | 24B |
| Accrued Liabilities | 24.9B |
| Other Current Liabilities | 62.2B |
| Non-Current Liabilities | 44.1B |
| Long-Term Debt | 20.2B |
| Other Non-Current Liabilities | 23.8B |
Balance Sheet
Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical Co Ltd
Currency: JPY
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
25 733
|
23 073
|
23 924
|
30 532
|
37 856
|
45 307
|
52 964
|
72 791
|
79 951
|
89 210
|
|
| Cash Equivalents |
25 733
|
23 073
|
23 924
|
30 532
|
37 856
|
45 307
|
52 964
|
72 791
|
79 951
|
89 210
|
|
| Total Receivables |
38 798
|
48 824
|
46 096
|
49 964
|
44 364
|
50 416
|
47 865
|
51 682
|
60 656
|
69 115
|
|
| Accounts Receivables |
38 798
|
48 824
|
46 096
|
49 964
|
44 364
|
50 416
|
47 865
|
51 682
|
60 656
|
69 115
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
22 568
|
23 035
|
23 609
|
26 228
|
30 260
|
31 223
|
27 925
|
33 527
|
41 062
|
46 657
|
|
| Other Current Assets |
6 593
|
6 820
|
7 319
|
3 326
|
3 922
|
3 760
|
4 317
|
6 306
|
8 577
|
9 777
|
|
| Total Current Assets |
93 692
|
101 752
|
100 948
|
110 050
|
116 402
|
130 706
|
133 071
|
164 306
|
190 246
|
214 759
|
|
| PP&E Net |
50 370
|
48 040
|
45 834
|
47 193
|
47 421
|
48 539
|
49 790
|
62 839
|
66 182
|
68 607
|
|
| PP&E Gross |
50 370
|
48 040
|
45 834
|
47 193
|
47 421
|
48 539
|
49 790
|
0
|
66 182
|
68 607
|
|
| Accumulated Depreciation |
65 676
|
68 180
|
70 588
|
74 496
|
77 643
|
84 622
|
86 877
|
0
|
106 462
|
113 801
|
|
| Intangible Assets |
3 050
|
2 372
|
1 928
|
2 605
|
2 482
|
2 685
|
4 590
|
6 587
|
6 997
|
6 932
|
|
| Goodwill |
1 326
|
1 130
|
735
|
1 503
|
1 083
|
2 445
|
3 304
|
2 954
|
2 564
|
2 285
|
|
| Note Receivable |
1 869
|
0
|
3 203
|
2 799
|
2 837
|
3 097
|
3 361
|
0
|
5 687
|
5 990
|
|
| Long-Term Investments |
24 325
|
21 405
|
27 502
|
32 328
|
28 530
|
23 880
|
26 226
|
28 132
|
33 637
|
44 337
|
|
| Other Long-Term Assets |
2 877
|
2 304
|
1 393
|
1 688
|
2 198
|
4 292
|
5 807
|
10 058
|
4 364
|
3 265
|
|
| Other Assets |
1 326
|
1 130
|
735
|
1 503
|
1 083
|
2 445
|
3 304
|
2 954
|
2 564
|
2 285
|
|
| Total Assets |
177 509
N/A
|
179 573
+1%
|
181 543
+1%
|
198 166
+9%
|
200 953
+1%
|
215 644
+7%
|
226 149
+5%
|
274 876
+22%
|
309 677
+13%
|
346 175
+12%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
10 201
|
12 355
|
12 151
|
15 072
|
14 068
|
14 243
|
11 330
|
16 269
|
18 718
|
21 123
|
|
| Accrued Liabilities |
29 555
|
29 725
|
26 316
|
27 544
|
28 871
|
29 485
|
26 398
|
19 354
|
25 544
|
27 292
|
|
| Short-Term Debt |
7 197
|
3 807
|
3 038
|
3 516
|
3 378
|
734
|
534
|
0
|
694
|
1 373
|
|
| Current Portion of Long-Term Debt |
3 810
|
3 361
|
3 041
|
3 470
|
3 301
|
4 519
|
5 152
|
8 033
|
7 613
|
8 092
|
|
| Other Current Liabilities |
6 844
|
10 109
|
8 876
|
11 730
|
11 142
|
13 136
|
13 057
|
27 832
|
27 593
|
29 207
|
|
| Total Current Liabilities |
57 607
|
59 357
|
53 422
|
61 332
|
60 760
|
62 117
|
56 471
|
71 488
|
80 162
|
87 087
|
|
| Long-Term Debt |
1 128
|
1 035
|
1 765
|
1 768
|
1 483
|
5 469
|
5 971
|
13 350
|
8 700
|
6 688
|
|
| Deferred Income Tax |
3 260
|
2 300
|
2 492
|
987
|
255
|
716
|
998
|
0
|
1 173
|
1 597
|
|
| Minority Interest |
425
|
462
|
434
|
755
|
917
|
749
|
704
|
5 594
|
5 508
|
710
|
|
| Other Liabilities |
4 998
|
5 610
|
5 428
|
5 639
|
6 266
|
7 310
|
6 097
|
6 044
|
4 564
|
3 767
|
|
| Total Liabilities |
67 418
N/A
|
68 764
+2%
|
63 541
-8%
|
70 481
+11%
|
69 681
-1%
|
76 361
+10%
|
70 241
-8%
|
96 476
+37%
|
100 107
+4%
|
99 849
0%
|
|
| Equity | |||||||||||
| Common Stock |
6 411
|
6 411
|
6 415
|
6 415
|
6 446
|
6 504
|
6 504
|
6 504
|
6 504
|
6 504
|
|
| Retained Earnings |
92 883
|
99 243
|
106 862
|
113 256
|
120 487
|
132 367
|
145 893
|
162 686
|
184 387
|
209 781
|
|
| Additional Paid In Capital |
5 738
|
5 738
|
5 737
|
5 737
|
5 603
|
5 661
|
5 661
|
5 791
|
5 292
|
4 516
|
|
| Unrealized Security Profit/Loss |
6 646
|
0
|
5 862
|
8 220
|
6 279
|
4 144
|
6 717
|
5 992
|
7 951
|
11 276
|
|
| Treasury Stock |
5 451
|
0
|
4 938
|
4 935
|
4 935
|
4 935
|
4 936
|
4 936
|
4 938
|
4 939
|
|
| Other Equity |
3 864
|
814
|
1 936
|
1 008
|
2 608
|
4 458
|
3 931
|
2 363
|
10 374
|
19 188
|
|
| Total Equity |
110 091
N/A
|
110 809
+1%
|
118 002
+6%
|
127 685
+8%
|
131 272
+3%
|
139 283
+6%
|
155 908
+12%
|
178 400
+14%
|
209 570
+17%
|
246 326
+18%
|
|
| Total Liabilities & Equity |
177 509
N/A
|
179 573
+1%
|
181 543
+1%
|
198 166
+9%
|
200 953
+1%
|
215 644
+7%
|
226 149
+5%
|
274 876
+22%
|
309 677
+13%
|
346 175
+12%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
114
|
114
|
228
|
228
|
228
|
228
|
228
|
228
|
228
|
228
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
